StockData
NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW

NeuroSense Therapeutics Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$2.67−0.40 (-13.19%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

NeuroSense Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements NeuroSense Therapeutics filed with the SEC